Amarin (AMRN) announced that Murray Stewart, D.M., F.R.C.P., has been appointed to the Company’s Board of Directors. Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70 percent of new independent directors who were named to the Board over the last 12 months. Dr. Stewart is a physician by training and brings more than 30 years of cardiometabolic academic and industry experience to the Amarin Board of Directors. Recently, Dr. Stewart was Chief Medical Officer at Rhythm Pharmaceuticals (RYTM).
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMRN:
- Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
- Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
- Jefferies upgrades ‘intriguing small cap value play’ Amarin to Buy
- Amarin upgraded to Buy from Hold at Jefferies
- Amarin in patent infringement settlement with Health Net, no terms